Parabilis Medicines, Inc. (NASDAQ:PBLS) Receives $41.67 Consensus Target Price from Analysts

Parabilis Medicines, Inc. (NASDAQ:PBLS) has received an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $41.6667.

Several analysts have recently weighed in on the company. Guggenheim started coverage on Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $40.00 price target on the stock. Lifesci Capital upgraded shares of Parabilis Medicines to a “strong-buy” rating in a report on Monday, July 6th. Bank of America began coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They set a “buy” rating and a $45.00 target price on the stock. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings raised shares of Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday.

Parabilis Medicines Price Performance

Shares of PBLS opened at $38.17 on Friday. Parabilis Medicines has a 52 week low of $24.51 and a 52 week high of $42.49. The firm has a fifty day moving average price of $36.22.

Parabilis Medicines (NASDAQ:PBLS) last issued its earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The business had revenue of $0.15 million during the quarter. As a group, analysts expect that Parabilis Medicines will post -2.05 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new position in Parabilis Medicines during the 2nd quarter worth about $134,647,000. ICONIQ Capital LLC acquired a new stake in shares of Parabilis Medicines in the second quarter valued at about $9,580,000. ARCH Venture Management LLC acquired a new stake in shares of Parabilis Medicines in the second quarter valued at about $175,517,789. Squarepoint Ops LLC bought a new position in shares of Parabilis Medicines during the second quarter worth about $1,327,000. Finally, General Catalyst Group Management LLC acquired a new position in shares of Parabilis Medicines in the second quarter worth approximately $43,818,000.

Parabilis Medicines Company Profile

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.